Definitive and neoadjuvant therapies for esophageal and gastroesophageal junction tumors: a look back and toward the future.
This article gives a brief discussion of "state-of-the-art" therapeutic strategies for esophageal and gastroesophageal junction tumors, with an emphasis on combined-modality therapy. In addition, we review the results of a multimodality trial conducted using a new agent against esophageal cancer, oxaliplatin. In this trial, the emphasis was on the efficacy and toxicity of oxaliplatin in combination with protracted infusion 5-fluorouracil and radiation. A secondary endpoint of the study was the relationship between efficacy and toxicity to specific intratumoral gene expressions within the primary esophageal tumor.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D004938:Esophageal Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000628:therapy*; D004943:Esophagogastric Junction; D005472:Fluorouracil / Q000008:administration & dosage; D015870:Gene Expression; D006801:Humans; D020360:Neoadjuvant Therapy; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D011879:Radiotherapy Dosage; D013274:Stomach Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000628:therapy*
D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D005472:Fluorouracil